by Cal Strode | Sep 15, 2022
OmniaBio Inc., a subsidiary of CCRM, is building the largest facility of its kind in Canada, providing specialized manufacturing to the flourishing cell and gene therapy (CGT) industry. The new contract development and manufacturing organization (CDMO) will focus on...
by Cal Strode | Aug 17, 2022
Launched in June of 2015, ExCellThera is a clinical-stage biotechnology company making strides in developing robust and cost-effective processes for growing blood stem cells for therapeutic use, backed by award-winning proprietary technology. The company was founded...
by CCRM Australia | Aug 1, 2022
This post is by Harmanpreet Harmanpreet, who interned with CCRM Australia. The CCRM Australia Training Program seeks to facilitate training for the future workforce of the Australian regenerative medicine sector and includes an internship program that accepts...
by Stacey Johnson | Nov 12, 2021
In 2016 I shared a list of podcasts that I thought Signals’ readers might enjoy. I think it’s definitely time to update that list, and I’m excited to tell you about a new podcast that’s about to launch: Commercializing Living Therapies with CCRM. Commercializing...
by Tara Fernandez | Jul 7, 2021
In early 2021, a young boy in Barcelona was the first to receive Pfizer’s investigational gene therapy for Duchenne muscular dystrophy (DMD). This was part of a global Phase 3 human trial to test Pfizer’s lead candidate, PF-06939926, in a cohort of 99 patients with...
by Stacey Johnson | Jun 25, 2021
Back in November 2020, California voters approved Proposition 14. That means US$5.5B is being directed to the California Institute for Regenerative Medicine (CIRM) to support promising cell and gene therapy research so the organization can continue the important work...
Comments